Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.


ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a given peptide, DACTM and PC-DACTM can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.

Investment year: 1998
Industry sector: Medical/health
Region: Quebec
Follow Conjuchem